PlainRecalls
FDA Drug Moderate Class II Ongoing

Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01

Reported: September 11, 2024 Initiated: August 22, 2024 #D-0651-2024

Product Description

Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01

Reason for Recall

Lack of Assurance of Sterility

Details

Recalling Firm
ProRx LLC
Units Affected
37 vials
Distribution
Nationwide in the USA
Location
Exton, PA

Frequently Asked Questions

What product was recalled?
Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01. Recalled by ProRx LLC. Units affected: 37 vials.
Why was this product recalled?
Lack of Assurance of Sterility
Which agency issued this recall?
This recall was issued by the FDA Drug on September 11, 2024. Severity: Moderate. Recall number: D-0651-2024.